Market revenue in 2022 | USD 1,888.4 million |
Market revenue in 2030 | USD 4,496.5 million |
Growth rate | 11.5% (CAGR from 2022 to 2030) |
Largest segment | Flow cytometry |
Fastest growing segment | Next Generation Sequencing (NGS) |
Historical data covered | 2018 - 2021 |
Base year for estimation | 2022 |
Forecast period covered | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Polymerase Chain Reaction (PCR), Flow Cytometry, Next Generation Sequencing (NGS) |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to minimal residual disease testing market will help companies and investors design strategic landscapes.
flow cytometry was the largest segment with a revenue share of 39.61% in 2022. Horizon Databook has segmented the Global minimal residual disease testing market based on polymerase chain reaction (pcr), flow cytometry, next generation sequencing (ngs) covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of global-level data and insights on the Global minimal residual disease testing market , including forecasts for subscribers. This global databook contains high-level insights into Global minimal residual disease testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account